Hi Vassilis
On 14/08/14 07:34, Vassilis Virvilis wrote:
Hi,
On 08/13/2014 06:43 PM, Sergey Beryozkin wrote:
On 13/08/14 15:43, Vassilis Virvilis wrote:
This however transmits the entities as one jsonified array with [{x:"a",
y:"b"}, {x:"c", y:"d"}] if you know what I mean. CXF in the other
doesn't parse it as per JAX-RS spec probably but I am not sure. So what
are the options?
What exactly doe it this mean :-) ? I.e, why are you making the
statement that CXF does not follow the spec ? I've no problems with
users pointing out to such issues, the more of them discovered the
better, but I haven't seen anything so far in this case that proves CXF
does not follow the spec
I have to apologize about that. This is not what I meant to say at all.
What I mean was: RestyGWT and CXF differ on how they put/expect the
@FormParam argument when there is a List involved. I tried to say (but
failed) that CXF probably __follows__ JAX-RS hence the difference but I
am not 100% certain. Why I am not 100% certain? Because I don't know the
spec but I know from all these years lurking on this list that CXF takes
the W3 standards and interoperability very seriously and strives to
fulfill them.
Hope this clears it up. I will take now a read on the spec and I will
follow up if I spot anything.
No problems at all, thanks for the clarifications. It's a bit of a grey
area, and I actually sent a message to the JAX-RS group to clarify. You
may well be right in the end :-). It's just a bit of a sensitive area, a
non-compliance will be addressed immediately if confirmed, but we need a
clear statement in the API docs or a message from a spec lead, etc.
Thanks, Sergey
Vassilis
__________________________________
Vassilis Virvilis Ph.D.
Head of IT
Biovista Inc.
US Offices
2421 Ivy Road
Charlottesville, VA 22903
USA
T: +1.434.971.1141
F: +1.434.971.1144
European Offices
34 Rodopoleos Street
Ellinikon, Athens 16777
GREECE
T: +30.210.9629848
F: +30.210.9647606
www.biovista.com
Biovista is a privately held biotechnology company that finds novel uses
for existing drugs, and profiles their side effects using their
mechanism of action. Biovista develops its own pipeline of drugs in CNS,
oncology, auto-immune and rare diseases. Biovista is collaborating with
biopharmaceutical companies on indication expansion and de-risking of
their portfolios and with the FDA on adverse event prediction.
